10-Q: Clene Inc. Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update

Clene Inc. reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and a recent capital raise, while also acknowledging substantial doubt about its ability to continue as a going concern.

Summary

• Clene Inc. is a clinical-stage pharmaceutical company focused on developing nanotechnology therapeutics, primarily for neurological disorders.
• The company reported a net loss of $7.99 million for the three months ended September 30, 2024, and a net loss of $25.85 million for the nine months ended September 30, 2024.
• Revenue for the quarter was $87,000, and $251,000 for the nine months, primarily from dietary supplement sales.
• Research and development expenses were $4.47 million for the quarter and $14.49 million for the nine months, reflecting ongoing clinical trial activities.
• The company's cash, cash equivalents, and marketable securities totaled $14.6 million as of September 30, 2024, down from $35.0 million at the end of 2023.
• Clene has raised $3.5 million from a registered direct offering and $3.8 million from private placements subsequent to the end of the quarter.
• The company has implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts and elimination of certain staff positions.
• There is substantial doubt about the company's ability to continue as a going concern due to its financial condition.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with positive clinical advancements but significant financial concerns, including a going concern warning. The sentiment is negative due to the financial instability and reliance on future funding.

Positives

• Clene is advancing its clinical programs for CNM-Au8 in ALS and MS.
• The company has secured additional funding through a registered direct offering and private placements.
• Clene is actively planning a Phase 3 trial for CNM-Au8 in ALS.
• The company is continuing to enroll patients in the REPAIR-MS trial.
• Clene is working closely with regulatory authorities to determine the best path forward for its drug candidates.

Negatives

• Clene has incurred significant losses and negative cash flows from operations.
• The company's cash reserves have decreased significantly.
• There is substantial doubt about Clene's ability to continue as a going concern.
• The company has implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts and elimination of certain staff positions.
• Clene has not generated significant revenue from drug sales.

Risks

• Clene's ability to obtain additional financing is uncertain.
• The company's drug candidates require regulatory approvals before commercial sales.
• Clene relies on third-party CROs and manufacturers.
• The company faces risks related to intellectual property protection and potential litigation.
• Clene's ability to attract and retain employees is critical to its growth.
• The company is subject to covenants under its term loan with Avenue, including maintaining a minimum cash balance.

Future Outlook

Clene plans to initiate a Phase 3 trial for CNM-Au8 in ALS in the second quarter of 2025, contingent on regulatory feedback and funding, and expects topline results from the second dosing cohort of REPAIR-MS by mid-2025. The company also plans to meet with the FDA in an end of Phase 2 meeting in the first half of 2025.

Management Comments

• Management believes the condensed consolidated financial statements fairly represent the company's financial condition, results of operations, and cash flows.
• Management has concluded that the company's plans do not alleviate the substantial doubt about its ability to continue as a going concern beyond one year from the date the condensed consolidated financial statements are issued.

Industry Context

The document highlights the challenges in developing effective treatments for ALS, noting the limited clinical successes and the recent withdrawal of a previously approved drug. This underscores the high unmet medical need and the potential market for successful therapies like Clene's CNM-Au8.

Comparison to Industry Standards

• Clene's financial results reflect the typical challenges faced by clinical-stage pharmaceutical companies, with significant R&D expenses and ongoing losses.
• The company's cash burn rate is a concern, as it is common for companies in this sector to require frequent capital raises.
• The planned Phase 3 trial for CNM-Au8 is a significant step, comparable to other companies advancing their lead drug candidates.
• The company's reliance on external funding is typical for companies in this stage of development, but the going concern warning is a significant concern.
• The company's revenue from dietary supplements is not a significant contributor to its overall financial performance, which is common for companies focused on drug development.

Related Party Transactions

• Clene has a license and supply agreement with 4Life Research LLC, a related party, for the sale of dietary supplements.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be affected by cost-saving initiatives, including potential staff reductions.
• Customers of Clene's dietary supplements may see changes in product availability or pricing.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• Clene plans to initiate a Phase 3 trial for CNM-Au8 in ALS in the second quarter of 2025.
• The company expects topline results from the second dosing cohort of REPAIR-MS by mid-2025.
• Clene plans to meet with the FDA in an end of Phase 2 meeting in the first half of 2025.
• The company will continue to seek additional funding through various means.

Key Dates

Keywords

CNM-Au8, ALS, Multiple Sclerosis, Nanotechnology, Clinical Trials, Pharmaceutical, Drug Development, Reverse Stock Split, Warrants, Going Concern, Capital Raise, Neurology